What Women Need to Know: Understanding the FDA's New Guidance on Hormone Replacement Therapy (HRT)

What the FDA's Updated Guidance Actually Says

The FDA's position on menopausal hormone therapy has shifted from blanket caution to individualized risk-benefit assessment. The agency now recognizes that for symptomatic women within 10 years of menopause onset, the benefits of HRT can outweigh the risks when therapy is appropriately selected and monitored [1].

The Core Recommendation

The updated framework centers on three principles: use the lowest effective dose, reassess annually, and match the formulation to the patient's symptom profile and risk factors. Systemic estrogen therapy remains the gold standard for moderate-to-severe vasomotor symptoms [2]. For women with an intact uterus, a progestogen must be co-prescribed to prevent endometrial hyperplasia.

What Changed From Prior Guidance

The shift is not a reversal but a recalibration. Earlier FDA communications, influenced heavily by initial Women's Health Initiative (WHI) results published in 2002, emphasized risks in broad terms that discouraged prescribing across all age groups. The updated guidance acknowledges what subgroup analyses later revealed: age at initiation and time since menopause are the two strongest modifiers of cardiovascular risk [3]. A 52-year-old woman starting estrogen for debilitating hot flashes carries a different risk profile than a 72-year-old starting therapy a decade after her last period.

Labeling Requirements

The FDA still requires a black box warning on all systemic estrogen and estrogen-progestogen products. This warning references increased risks of stroke, deep vein thrombosis, pulmonary embolism, and (for combined therapy) breast cancer [4]. The warning language has not been removed, but prescribing information now includes more detailed age-stratified data.

Why the FDA Revisited HRT After Two Decades

The 2002 WHI publication triggered a global decline in HRT prescribing that persists today. That single trial shaped a generation of clinical practice. Revisiting it required two decades of follow-up data, reanalysis, and pressure from both clinicians and patients.

The WHI: What It Found and What It Missed

The WHI enrolled 27,347 postmenopausal women aged 50 to 79 into two arms: conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) for women with a uterus, and CEE alone for women post-hysterectomy. The combined arm was stopped early after a median of 5.6 years when breast cancer incidence crossed a predefined boundary. The hazard ratio for invasive breast cancer was 1.26 (95% CI: 1.00 to 1.59) [5].

The estrogen-alone arm told a different story. Over a median 7.2-year follow-up, CEE alone showed a non-significant decrease in breast cancer risk (HR 0.77, 95% CI: 0.59 to 1.01) [6]. This finding was largely overshadowed by the combined-arm headlines.

The Age Problem

The mean age of WHI participants was 63. Only 33% were aged 50 to 59. Subgroup analyses published years later showed that women aged 50 to 59 who received CEE alone had a significantly lower risk of coronary heart disease and all-cause mortality compared to placebo [7]. The North American Menopause Society (NAMS) has cited this data in its 2022 position statement: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [8].

Prescribing Rates Never Recovered

Between 2001 and 2011, HRT prescriptions in the United States fell by roughly 80% [9]. Dr. JoAnn Manson, principal investigator of the WHI, stated in a 2024 JAMA editorial: "The pendulum swung too far. Many symptomatic women in their 50s were denied effective therapy based on data derived largely from women in their 60s and 70s" [10]. The FDA's updated guidance is, in part, a response to this overcorrection.

Who Qualifies for HRT Under Current Guidelines

Not every menopausal woman is a candidate. The FDA and major medical societies have outlined clear inclusion and exclusion criteria that clinicians should follow before prescribing.

Appropriate Candidates

The Endocrine Society's 2015 clinical practice guideline (reaffirmed in subsequent reviews) recommends menopausal hormone therapy for women who meet all of the following: symptomatic vasomotor symptoms that impair quality of life, age younger than 60 or within 10 years of menopause, and no absolute contraindications [11]. NAMS extends the indication to include genitourinary syndrome of menopause (GSM) and prevention of osteoporotic fractures in women at elevated risk [8].

Absolute Contraindications

The FDA lists the following as contraindications for systemic HRT: undiagnosed abnormal genital bleeding, known or suspected breast cancer, known or suspected estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease (stroke or MI), known liver dysfunction or disease, and known protein C/protein S/antithrombin deficiency [4].

The Gray Zone

Women with a history of VTE who are more than 10 years out, women with controlled hypertension, women with a BMI above 35: these fall into a gray zone where transdermal estradiol may be appropriate but oral estrogen is not. Transdermal estradiol at doses of 50 mcg/day or less does not appear to increase VTE risk, according to a meta-analysis of observational studies published in The Lancet (OR 0.93, 95% CI: 0.65 to 1.33) [12]. This route-specific distinction is a key update in current clinical thinking.

FDA-Approved HRT Formulations and Routes

The FDA has approved more than 50 hormone therapy products spanning multiple formulations. The choice of route matters for both efficacy and safety.

Systemic Options

Oral estradiol (0.5 mg, 1 mg, 2 mg) and conjugated equine estrogens (0.3 mg, 0.45 mg, 0.625 mg) remain the most commonly prescribed oral formulations. Transdermal patches deliver estradiol at 0.025 mg to 0.1 mg per day. Topical gels (EstroGel) and sprays (Evamist) offer additional transdermal options [13].

For progestogen coverage, options include oral micronized progesterone (Prometrium, 100 mg or 200 mg), medroxyprogesterone acetate, and the levonorgestrel-releasing IUD (Mirena), which the American College of Obstetricians and Gynecologists (ACOG) recognizes as providing adequate endometrial protection during estrogen therapy [14].

Local Vaginal Therapy

Low-dose vaginal estrogen (cream, tablet, ring) treats GSM without clinically significant systemic absorption. The FDA updated labeling for these products in 2022 to note that systemic estrogen exposure from low-dose vaginal formulations is minimal, and the black box warning may not apply to products delivering less than 10 mcg/day of estradiol [15]. This was a meaningful change for women with breast cancer histories who need vulvovaginal symptom relief.

Newer Approvals

Fezolinetant (Veozah), approved in 2023, is a non-hormonal neurokinin-3 receptor antagonist for vasomotor symptoms. It is not HRT, but the FDA approved it as an alternative for women who cannot or prefer not to use hormones. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flashes by 60.4% at week 12 versus 42.4% for placebo [16].

Compounded Bioidentical Hormones: What the FDA Warns About

The FDA has taken an increasingly firm stance against compounded bioidentical hormone therapy (cBHT), and the updated guidance reinforces this position.

The Distinction That Matters

"Bioidentical" refers to hormones structurally identical to those the human body produces: 17-beta estradiol, progesterone, estriol, testosterone. Many FDA-approved products already contain bioidentical hormones. The FDA's concern is not with the molecule but with the compounding process. Compounded products are not required to demonstrate safety, efficacy, or consistent potency through the FDA approval pathway [17].

FDA and NASEM Findings

A 2020 report from the National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that cBHT products "expose patients to risks that are not well-characterized" and recommended that the FDA consider designating certain cBHT formulations (pellets, combination products) as "demonstrably difficult to compound" [18]. The FDA's updated framework echoes this recommendation.

Dr. Janet Woodcock, then-acting FDA Commissioner, stated in an agency communication: "Patients deserve to know that compounded drugs have not undergone the premarket review that provides assurance of safety, effectiveness, and quality" [17].

What This Means for Patients

Women currently receiving compounded estradiol, progesterone, estriol, or testosterone pellets from compounding pharmacies should discuss FDA-approved alternatives with their prescriber. The FDA does not prohibit compounding but has increased scrutiny of pharmacies that produce large quantities of hormone preparations without individual prescriptions, a practice that blurs the line between compounding and manufacturing [17].

Risks and Benefits: What the Evidence Shows

Two decades of post-WHI data have produced a more granular picture of HRT's risk-benefit profile. The answer depends on the woman's age, time since menopause, formulation used, and baseline risk factors.

Cardiovascular Effects

For women initiating estrogen therapy within 10 years of menopause, the WHI estrogen-alone arm showed a trend toward reduced coronary heart disease (HR 0.63, 95% CI: 0.36 to 1.09 in the 50-to-59 subgroup) [7]. The Danish Osteoporosis Prevention Study (DOPS), a randomized trial that followed 1,006 women for 16 years, found that early initiation of HRT reduced the composite endpoint of death, heart failure, or myocardial infarction (HR 0.61, 95% CI: 0.39 to 0.94) [19].

For women initiating therapy more than 20 years after menopause, the WHI showed increased coronary events. This timing hypothesis is now central to all major guidelines.

Breast Cancer

The combined estrogen-plus-progestogen arm of the WHI showed an attributable risk of approximately 8 additional cases of invasive breast cancer per 10,000 women per year of use [5]. For context, this is similar to the breast cancer risk increase associated with consuming two or more alcoholic drinks daily or being obese after menopause [20].

Estrogen alone did not increase breast cancer risk in the WHI. After 18 years of cumulative follow-up, women who had received CEE alone continued to show lower breast cancer incidence and mortality compared to placebo [21].

Bone Health

Estrogen therapy reduces hip fracture risk by approximately 34%. In the WHI, the hip fracture HR was 0.66 (95% CI: 0.45 to 0.98) for the combined arm [5]. This benefit disappears within 2 to 3 years of stopping therapy, which is why the Endocrine Society recommends transitioning to a bone-specific agent (bisphosphonate or denosumab) if osteoporosis protection was a primary goal [11].

Cognitive Outcomes

The WHI Memory Study (WHIMS) found increased dementia risk in women aged 65 and older who initiated combined HRT [22]. Observational data suggest a different picture for younger initiators. A Finnish registry study of nearly 85,000 women found that HRT use starting in the early postmenopausal period was associated with reduced Alzheimer's disease risk (HR 0.70, 95% CI: 0.63 to 0.77) [23]. Randomized data for this age group remain limited.

How Long Can You Stay on HRT?

The FDA recommends using "the lowest effective dose for the shortest duration consistent with treatment goals." This phrase has generated confusion among both patients and clinicians.

Annual Reassessment, Not Arbitrary Cutoffs

NAMS and the Endocrine Society recommend annual reassessment rather than a fixed stopping point [8][11]. If symptoms recur after a dose reduction or discontinuation attempt (which happens in up to 50% of women), resumption is appropriate. There is no evidence-based maximum duration for HRT in women who remain symptomatic and continue to have a favorable risk profile.

Tapering Versus Abrupt Discontinuation

A Cochrane review found no difference in symptom recurrence rates between gradual tapering and abrupt cessation, though patient preference generally favors tapering [24]. A common approach is reducing the estradiol dose by 50% for 3 to 6 months before stopping.

Extended Use Scenarios

Some women remain on low-dose HRT into their late 60s or 70s for persistent vasomotor symptoms or GSM. The decision requires shared decision-making, documented informed consent, and ongoing monitoring. For women using vaginal estrogen only, duration limits are generally not applied, and the FDA's updated labeling supports long-term use of low-dose local therapy [15].

What to Discuss With Your Doctor Before Starting

A prescriber visit for HRT should cover specific clinical data points, not just a symptom checklist.

Required Baseline Workup

Before initiating systemic HRT, clinicians should obtain: a current mammogram (within 12 months), blood pressure measurement, lipid panel, fasting glucose or HbA1c, assessment of VTE risk factors, and a thorough personal and family history of breast cancer, ovarian cancer, and cardiovascular disease [11]. A DEXA scan is appropriate if osteoporosis prevention is part of the rationale for therapy.

Questions to Ask Your Prescriber

Bring these to the appointment: What formulation do you recommend and why? Is transdermal estradiol safer for me than oral? Do I need a progestogen, and which type? How often will we reassess? What symptoms should prompt me to call between visits? Are there FDA-approved alternatives if I cannot tolerate hormones?

Red Flags During Therapy

Seek immediate evaluation for: unilateral leg swelling or pain, sudden chest pain or shortness of breath, new-onset severe headache, unscheduled vaginal bleeding after the first 6 months of therapy, or breast lump. These warrant urgent workup and possible therapy discontinuation pending results [4].

Routine follow-up should occur at 3 months after initiation and every 6 to 12 months thereafter, with annual mammography and clinical breast exam per ACOG guidelines [14].